8 Accordingly, two doses of OCR, 200 mg and 500 mg, were selected for further phase III investigation.
Our simulations predicted that the two dosing regimens (10 mg q4wk and 10 mg q6wk) selected for the phase III studies are expected to be efficacious and able to achieve near-complete target suppression in the vitreous humor.
A formulation consisting RB (50 mg), HPMC K4M, PVA, and PEO (63 mg), glycerol (1.5 ml), stevia (5 mg) was selected as our optimum composition.
19 The recommended dose of PHEN/TPM is 7.5/46 mg; for selected patients, full-dose (15/92 mg) may be a consideration.
600 mg size selected NaCl crystals (Merck, Darmstadt, Germany) with sizes between 40 and 100 µm were added to 150 mg of the PEG-diacrylate/RGD solution (final porogen concentration: 80% (w/w)).
Therefore, 4 mg baricitinib was considered the optimal dose for evaluation in phase III RA studies with this compound, with 2 mg baricitinib selected as the less effective dose.
The modified SANS, containing glucosamine (150 mg), was selected for in-vivo studies as it had a sustained drug release profile and a small particle size (173.90 nm).
For the isotopic analysis, further 100 mg from selected samples were reduced in powder in an agate mortar.
For our experiments Cu, Al, and Mg were selected as matrices.
Cilengitide 2000 mg was selected for the subsequent randomized phase II part assessing progression-free survival (PFS).
